Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel with Antiandrogen for Rising PSA Prostate Cancer
NCT03119857Phase 3Unknown
- Sponsor
- University of Gothenburg
- Start
- Feb 2009
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by University of Gothenburg. Primary endpoint: Progression free survival at 60 months. Status: unknown.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03119857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119857.